INTERNATIONAL WORKSHOP ON SCLERODE… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2016

Legal Domicile

Principal Officer

ROBERT LAFYATIS MD

Phone

6176861754

Tax Period

2023-01-01 to 2023-12-31

INTERNATIONAL WORKSHOP ON SCLERODERMA RESEARCH CORPORATION, founded in 2016, is a micro nonprofit in the Diseases & Disorders sector that reported $20K in total revenue in fiscal year 2023. Revenue fell 94% from the prior year — a significant decline worth monitoring. The organization ran a surplus of $18K, a strong 89% operating margin.

Mission

ORGANIZE AND IMPLEMENT RESEARCH MEETINGS THAT FOCUS ON SCLERODERMA RESEARCH

Program Service Accomplishments

Program 1

Expenses: $2,104

INTERNATIONAL WORKSHOP ON SCLERODERMA RESEARCH. CORPORATION HOLDS BIENNIAL CONFERENCES, THEREFORE, THE 16TH ANNUAL EVENT WAS HELD ON JULY 27TH OF 2019. NO ACTIVITY OCCURED IN 2020 AND 2021 DUE TO...

INTERNATIONAL WORKSHOP ON SCLERODERMA RESEARCH. CORPORATION HOLDS BIENNIAL CONFERENCES, THEREFORE, THE 16TH ANNUAL EVENT WAS HELD ON JULY 27TH OF 2019. NO ACTIVITY OCCURED IN 2020 AND 2021 DUE TO COVID.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $20,000

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $20,000

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $2,104

Other Expenses $2,104

TOTAL EXPENSES $2,104

Year-over-Year Comparison

	2023	2022	Change
Revenue	$20,000	$344,059	-0.9%
Expenses	$2,104	$389,505	-1.0%
Net Income	$17,896	$-45,446	-1.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ROBERT LAFYATIS MD	PRESIDENT	1.00	Officer Director	$0	$0	$0
CATHERINE BRENNAN	CLERK	1.00	Officer Director	$0	$0	$0
CAROL FEGHALI-BOSTICK PHD	DIRECTOR	1.00	Director	$0	$0	$0
MARIA TROJANOWSKA PHD	DIRECTOR	1.00	Director	$0	$0	$0
MICHAEL WHITFIELD PHD	DIRECTOR	1.00	Director	$0	$0	$0
JOHN VARGA MD	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2023	$20,000	$2,104	$79,001	$17,896
2022	$344,059	$389,505	$61,105	$-45,446
2021	No data	$1,011	$106,551	No data
2020	No data	$13,728	$107,562	No data

INTERNATIONAL WORKSHOP ON SCLERODERMA RESEARCH CORPORATION